Adenosine vs Diltiazem for Treatment of SVT in the ED

NCT06993038 | Recruiting Phase 4 FDA Drug

• 1 other identifier: 202412202
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.

Conditions

Supraventricular Tachycardia (SVT)

Keywords

diltiazem; adenosine; emergency medicine

Outcome Measures

Primary Outcomes (3)

• Feasibility outcome

  Patients with stable SVT are identified in the ED (Threshold \>90%)

  From enrollment to the end of ED encounter (up to 24 hours).

• Feasibility outcome

  Eligible participants who provide consent to participate (Threshold \>50%)

  From enrollment to the end of ED encounter (up to 24 hours).

• Feasibility outcome

  Participants who complete all study procedures (Threshold \>80%)

  From enrollment to the end of ED encounter (up to 24 hours).

Study Arms (2)

Adenosine

ACTIVE COMPARATOR

Drug: adenosine

Diltiazem

ACTIVE COMPARATOR

Drug: diltiazem

Interventions

adenosine DRUG

IV adenosine at standard doses for SVT (6 mg, 12 mg)

Adenosine

diltiazem DRUG

IV diltiazem at standard doses for SVT (0.25 mg/kg)

Diltiazem

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adult patients (18 years and older)
• Diagnosis of acute, stable SVT in the emergency department

You may not qualify if:

• Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting).
• Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome
• History of heart failure with reduce ejection fraction (HFrEF) (LVEF\</= 40%)
• Severe bronchoconstrictive lung disease
• Prior hypersensitivity to study medication
• Previously enrolled in pilot study
• Pregnant
• Incarcerated

Sponsors & Collaborators

• Anne E. Zepeski: lead

Study Sites (1)

University of Iowa Health Care

Iowa City, Iowa, 52242, United States

RECRUITING

MeSH Terms

Conditions

Tachycardia, Supraventricular

Interventions

Adenosine; Diltiazem

Condition Hierarchy (Ancestors)

Tachycardia; Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Cardiac Conduction System Disease; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Purine Nucleosides; Purines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Ribonucleosides; Benzazepines

Study Officials

• Anne Zepeski, PharmD

  University of Iowa

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Anne Zepeski, PharmD

CONTACT

(319) 356-2577; anne-zepeski@uiowa.edu

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Clinical Assistant Professor

Study Record Dates

• First Submitted: April 3, 2025
• First Posted: May 28, 2025
• Study Start: August 1, 2025
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): December 1, 2026
• Last Updated: September 11, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)